Literature DB >> 30859181

A novel mouse model of sporadic colon cancer induced by combination of conditional Apc genes and chemical carcinogen in the absence of Cre recombinase.

Jeffrey S Souris1, Hannah J Zhang1, Urszula Dougherty2, Nai-Tzu Chen3, Joseph V Waller1, Leu-Wei Lo1,4, John Hart5, Chin-Tu Chen1, Marc Bissonnette2.   

Abstract

Although valuable insights into colon cancer biology have been garnered from human colon cancer cell lines and primary colonic tissues, and animal studies using human colon cancer xenografts, immunocompetent mouse models of spontaneous or chemically induced colon cancer better phenocopy human disease. As most sporadic human colon tumors present adenomatous polyposis coli (APC) gene mutations, considerable effort has gone into developing mice that express mutant Apc alleles that mimic human colon cancer pathogenesis. A serious limitation of many of these Apc-mutant murine models, however, is that these mice develop numerous tumors in the small intestine but few, if any, in the colon. In this work, we examined three spontaneous mouse models of colon tumorigenesis based upon the widely used multiple intestinal neoplasia (Min) mouse: mice with either constitutive or conditional Apc mutations alone or in combination with caudal-related homeobox transcription factor CDX2P-Cre transgene - either with or without exposure to the potent colon carcinogen azoxymethane. Using the CDX2 promoter to drive Cre recombinase transgene expression effectively inactivated Apc in colonocytes, creating a model with earlier tumor onset and increased tumor incidence/burden, but without the Min mouse model's small intestine tumorigenesis and susceptibility to intestinal perforation/ulceration/hemorrhage. Most significantly, azoxymethane-treated mice with conditional Apc expression, but absent the Cre recombinase gene, demonstrated nearly 50% tumor incidence with two or more large colon tumors per mouse of human-like histology, but no small intestine tumors - unlike the azoxymethane-resistant C57BL/6J-background Min mouse model. As such this model provides a robust platform for chemoprevention studies.
© The Author(s) 2019. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30859181      PMCID: PMC6875902          DOI: 10.1093/carcin/bgz050

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  57 in total

1.  Azoxymethane is a genetic background-dependent colorectal tumor initiator and promoter in mice: effects of dose, route, and diet.

Authors:  Anika Bissahoyo; R Scott Pearsall; Kathleen Hanlon; Vicky Amann; Donna Hicks; Virginia L Godfrey; David W Threadgill
Journal:  Toxicol Sci       Date:  2005-09-08       Impact factor: 4.849

Review 2.  The clinical perspectives of CDX2 expression in colorectal cancer: a qualitative systematic review.

Authors:  J Olsen; M L M Espersen; P Jess; L T Kirkeby; J T Troelsen
Journal:  Surg Oncol       Date:  2014-07-17       Impact factor: 3.279

3.  Age-dependent susceptibility to azoxymethane-induced and spontaneous tumorigenesis in the Min/+ mouse.

Authors:  Jan Erik Paulsen; Inger-Lise Steffensen; Ellen Namork; Tor Jacob Eide; Jan Alexander
Journal:  Anticancer Res       Date:  2003 Jan-Feb       Impact factor: 2.480

4.  Independent control of immunoglobulin switch recombination at individual switch regions evidenced through Cre-loxP-mediated gene targeting.

Authors:  H Gu; Y R Zou; K Rajewsky
Journal:  Cell       Date:  1993-06-18       Impact factor: 41.582

5.  Immunohistochemical staining patterns of MUC1, MUC2, MUC4, and MUC5AC mucins in hyperplastic polyps, serrated adenomas, and traditional adenomas of the colorectum.

Authors:  A E Biemer-Hüttmann; M D Walsh; M A McGuckin; Y Ajioka; H Watanabe; B A Leggett; J R Jass
Journal:  J Histochem Cytochem       Date:  1999-08       Impact factor: 2.479

Review 6.  Cancer-associated mucins: role in immune modulation and metastasis.

Authors:  Rakesh Bhatia; Shailendra K Gautam; Andrew Cannon; Christopher Thompson; Bradley R Hall; Abhijit Aithal; Kasturi Banerjee; Maneesh Jain; Joyce C Solheim; Sushil Kumar; Surinder K Batra
Journal:  Cancer Metastasis Rev       Date:  2019-06       Impact factor: 9.264

Review 7.  Animal models of colorectal cancer.

Authors:  Robert L Johnson; James C Fleet
Journal:  Cancer Metastasis Rev       Date:  2013-06       Impact factor: 9.264

Review 8.  Recent insights into the biological roles of mucin-type O-glycosylation.

Authors:  E Tian; Kelly G Ten Hagen
Journal:  Glycoconj J       Date:  2008-08-10       Impact factor: 2.916

9.  Regulation of the tumor suppressor homeogene Cdx2 by HNF4α in intestinal cancer.

Authors:  T Saandi; F Baraille; L Derbal-Wolfrom; A-L Cattin; F Benahmed; E Martin; P Cardot; B Duclos; A Ribeiro; J-N Freund; I Duluc
Journal:  Oncogene       Date:  2012-09-17       Impact factor: 9.867

10.  Characterization of the MUC1.Tg/MIN transgenic mouse as a model for studying antigen-specific immunotherapy of adenomas.

Authors:  Emmanuel T Akporiaye; Deborah Bradley-Dunlop; Sandra J Gendler; Pinku Mukherjee; Cathy S Madsen; Tobias Hahn; David G Besselsen; Sharon M Dial; Haiyan Cui; Katrina Trevor
Journal:  Vaccine       Date:  2007-07-24       Impact factor: 3.641

View more
  4 in total

Review 1.  The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer.

Authors:  Lulu Sun; Jie Cai; Frank J Gonzalez
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-02-10       Impact factor: 46.802

2.  Increased Incidence of Colon Tumors in AOM-Treated Apc 1638N/+ Mice Reveals Higher Frequency of Tumor Associated Neutrophils in Colon Than Small Intestine.

Authors:  Rebecca Metzger; Mahulena Maruskova; Sabrina Krebs; Klaus-Peter Janssen; Anne B Krug
Journal:  Front Oncol       Date:  2019-10-02       Impact factor: 6.244

Review 3.  Mouse Models for Application in Colorectal Cancer: Understanding the Pathogenesis and Relevance to the Human Condition.

Authors:  Chuangen Li; Harry Cheuk-Hay Lau; Xiang Zhang; Jun Yu
Journal:  Biomedicines       Date:  2022-07-15

4.  Complement downregulation promotes an inflammatory signature that renders colorectal cancer susceptible to immunotherapy.

Authors:  Carsten Krieg; Lukas M Weber; Bruno Fosso; Marinella Marzano; Gary Hardiman; Monica M Olcina; Enric Domingo; Sahar El Aidy; Khalil Mallah; Mark D Robinson; Silvia Guglietta
Journal:  J Immunother Cancer       Date:  2022-09       Impact factor: 12.469

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.